StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)

Stock analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Up 0.9 %

Shares of NASDAQ BPTH opened at $1.16 on Friday. Bio-Path has a 1 year low of $0.59 and a 1 year high of $12.00. The stock’s 50-day simple moving average is $0.90 and its 200-day simple moving average is $1.21.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.